title: Metabolic issues in psychotic disorders with the focus on first-episode patients: a review.
abstract: Before the onset of the illness, future schizophrenia patients do not weigh more comparing to their peers. However, during the later course of the illness, obesity is twice as prevalent as in general public, afflicting the half of schizophrenia patient population. There is a list of potential factors that contribute to this, including lifestyle, dietary habits, unsatisfactory monitoring of physical health etc, but nowadays side effects of antipsychotic medication become the most prominent concern when weight gain and metabolic issues in psychosis are addressed. The fact is that second generation antipsychotics (SGA) are associated with weight gain and metabolic syndrome, but that might be the case with the first generation antipsychotics (FGA) too. Besides, obesity might be evident in patients before any exposure to medications, and all that bring lot of dilemmas into the field. This paper critically reviews available data on metabolic problems in patients with psychotic disorders, raging from genetic to molecular and environmental factors, and highlights the necessity of screening for the early signs of metabolic disturbances, as well as of multidisciplinary assessment of psychiatric and medical conditions from the first psychotic episode.
authors.affiliation: Clinic for Psychiatry, University Clinical Center of Serbia, Pasterova 2, 11000 Belgrade, Serbia.
authors.forename: Dubravka
authors.initials: D
authors.lastname: Britvic
authors.forename: Nadja P
authors.initials: NP
authors.lastname: Maric
authors.forename: Mirjana
authors.initials: M
authors.lastname: Doknic
authors.forename: Sandra
authors.initials: S
authors.lastname: Pekic
authors.forename: Sanja
authors.initials: S
authors.lastname: Andric
authors.forename: Miroslava
authors.initials: M
authors.lastname: Jasovic-Gasic
authors.forename: Vera
authors.initials: V
authors.lastname: Popovic
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000378:metabolism*; D006801:Humans; D024821:Metabolic Syndrome / Q000139:chemically induced* / Q000150:complications / Q000378:metabolism*; D009765:Obesity; D011618:Psychotic Disorders / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D015430:Weight Gain / Q000187:drug effects*
chemical_list: D014150:Antipsychotic Agents